This Extraordinary Shareholders' Meeting, called by ASIT Biotech's Board of Directors, provided an opportunity to have a discussion on whether the Company's strategy justifies or not the need to call for further authorized capital for a 5-year period. Shareholders overwhelmingly rejected this request and, accordingly, approved a renewal of the members of the Board of Directors.
The Extraordinary Shareholders' Meeting approved the appointment of two new Board members with recognized expertise in the field of immunotherapy and biotechs, namely Mr. Louis Champion and Mr. Michel Baijot, following the departure from the Board of Directors of Mr. Gerd Zettlmeissl, Mr. Thierry Legon and Mr. Jean Duchateau. The Board of Directors then today approved the appointment of Mr. Louis Champion as Chairman of the Board of Directors and Mr. Michel Baijot as Managing Director, providing the Company with significant expertise of the biotech and big pharma fields.
Pour recevoir toute l'information financière d'ASIT biotech en temps réel, faites-en la demande par mail à asitbiotech@newcap.eu. Votre inscription sera immédiate.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer